Boston sells Prolieve back to originator for just $5m
This article was originally published in Clinica
Executive Summary
Boston Scientific has sold its Prolieve benign prostatic hyperplasia (BPH) therapy back to the technology's originator Medifocus for $5m, a fraction of the price Boston originally paid for it. Boston acquired the product in 2007 for $60m through Medifocus's subsidiary Celsion (www.clinica.co.uk, 27 April 2007).